ICU Medical (NASDAQ:ICUI) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen lowered shares of ICU Medical (NASDAQ:ICUI) from a buy rating to a hold rating in a report released on Sunday.

A number of other equities research analysts also recently weighed in on the company. Piper Sandler boosted their price target on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. KeyCorp lifted their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical currently has an average rating of “Moderate Buy” and an average target price of $175.67.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $152.99 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. ICU Medical has a 1 year low of $107.00 and a 1 year high of $175.51. The firm’s 50-day simple moving average is $143.10 and its 200-day simple moving average is $131.46. The firm has a market cap of $3.78 billion, a PE ratio of -493.50 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The business had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. During the same period last year, the firm earned $1.59 earnings per share. The company’s revenue for the quarter was down 8.9% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Equities analysts forecast that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other news, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares in the company, valued at approximately $560,977.90. This represents a 24.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the sale, the vice president directly owned 5,456 shares in the company, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their position. The SEC filing for this sale provides additional information. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System increased its stake in shares of ICU Medical by 1.3% in the third quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock valued at $828,000 after purchasing an additional 91 shares during the period. Moody National Bank Trust Division boosted its position in shares of ICU Medical by 0.9% during the second quarter. Moody National Bank Trust Division now owns 10,751 shares of the medical instruments supplier’s stock worth $1,421,000 after buying an additional 93 shares during the period. Smartleaf Asset Management LLC grew its holdings in ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares in the last quarter. BNP Paribas Financial Markets increased its position in ICU Medical by 4.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock valued at $325,000 after acquiring an additional 107 shares during the period. Finally, Thrivent Financial for Lutherans increased its position in ICU Medical by 0.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 18,098 shares of the medical instruments supplier’s stock valued at $2,392,000 after acquiring an additional 114 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.